| Dermatitis, Atopic
Ebglyss vs Nemluvio
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Ebglyss vs Nemluvio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNemluvio has a higher rate of injection site reactions vs Ebglyss based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nemluvio but not Ebglyss, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ebglyss
Nemluvio
At A Glance
SC injection
Every 2-4 weeks
IL-13 antagonist
SC injection
Every 4 weeks
IL-31 receptor antagonist
Indications
- Dermatitis, Atopic
- Prurigo nodularis
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic 500 mg (two 250 mg injections) SC at Week 0 and Week 2, then 250 mg every 2 weeks until Week 16 or adequate clinical response; maintenance dose is 250 mg every 4 weeks SC.
Prurigo nodularis (<90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks.
Prurigo nodularis (>=90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 60 mg SC every 4 weeks.
Dermatitis, Atopic Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks; after 16 weeks, patients who achieve clear or almost clear skin may receive 30 mg every 8 weeks.
Contraindications
- Prior serious hypersensitivity to lebrikizumab-lbkz or any excipient of EBGLYSS
- Known hypersensitivity to nemolizumab-ilto or any excipient in NEMLUVIO
Adverse Reactions
Most common (>=1%) conjunctivitis, injection site reactions, herpes zoster
Serious hypersensitivity, conjunctivitis, keratitis
Most common (>=1%) Headache, dermatitis atopic, eczema, eczema nummular (prurigo nodularis trials); headache, arthralgia, urticaria, myalgia (atopic dermatitis trials).
Serious Type 1 hypersensitivity reactions (IgE-mediated), including facial angioedema.
Pharmacology
Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity to IL-13, inhibiting IL-13 signaling through the IL-4Ra/IL-13Ra1 receptor complex; IL-13 is a cytokine central to Type 2 inflammation in atopic dermatitis pathogenesis.
Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 receptor alpha (IL-31 RA); IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ebglyss
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Nemluvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ebglyss
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (4/8)
Nemluvio
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (4/8)
Humana
Ebglyss
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Nemluvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Ebglyss Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EbglyssView full Ebglyss profile
NemluvioView full Nemluvio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.